Mark L. Baum

Chief Executive Officer
Member, Board of Directors

Mr. Baum is a founder, board member and CEO of Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY). Beginning in 2011, Mr. Baum led the restructuring and reorganization of Imprimis,

read more »

Andrew R. Boll

Vice-President, Accounting & Public Reporting

Mr. Boll, has over eight years of experience in financial reporting and accounting with a significant portion of that experience working with small capitalization companies, with a particular focus on restructured and reorganized businesses.

read more »

Gary Seelhorst

Vice-President, Corporate Development

Mr. Seelhorst, has over 17 years of clinical and corporate development experience with both large-cap pharmaceutical companies (e.g. Eli Lilly and Pfizer) as well as start-up ventures including extensive capital raising, licensing, and M&A transactions.

read more »

Victor Repkin

Intellectual Property Analyst

Victor Repkin, Ph.D., has served as patent attorney and intellectual property analyst for Imprimis Pharmaceuticals since June 2013.  Dr. Repkin has more than 15 years of experience in patent preparation and prosecution, patent counseling and due diligence.

read more »

John Saharek

Vice‐President of Commercialization, Ophthalmology

Mr. Saharek is an experienced ophthalmology industry leader with a 30 year track record of building high performing commercial teams, developing and executing strategic plans, building brands, launching products and delivering outstanding results for a variety of healthcare companies.

read more »